+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Growth Opportunities in Vaccines, Gene Therapy, and Stem Cell Therapy

  • PDF Icon


  • 35 Pages
  • April 2021
  • Region: Global
  • Frost & Sullivan
  • ID: 5390098

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) discusses multiple developments in vaccine technologies, both prophylactic and therapeutic. Most of the innovations highlighted are around influenza, COVID-19, and cancer vaccines. Developments in intranasal delivery, needle-free delivery, and thermostable formulations are also covered. Advanced technology platforms for scalable manufacturing and plug and play solutions, which can be applied to multiple pathogen serotypes are also discussed. Further, innovations in emerging technologies such as gene therapy for retinal diseases, immunotherapy for cancers, developments in nutraceuticals for cardiovascular protection and cosmeceuticals for skin and hair care and protein-based sweeteners are also profiled in this TOE.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Table of Contents

Innovations in Life Sciences, Health & Wellness

  • Altimmune, US
  • Serum Institute of India Pvt. Ltd., India
  • Nouscom, Switzerland
  • Vaxart, US
  • Gpn Vacccines, Australia
  • Providence Therapeutics, Canada
  • 2A Pharma Aps, Denmark
  • Vaccitech, UK
  • Affinivax, US
  • Minervax, Denmark
  • Codagenix, US
  • Vaxxas Inc., US
  • Gradalis Inc., US
  • Gotham Therapeutics Corporation, US
  • Flavex Naturextrakte Gmbh, Germany
  • Enovate Biolife, India
  • Gyroscope Therapeutics, UK
  • Rinri Therapeutics, UK
  • Bharat Biotech International Limited, India
  • Sanaria Inc., US
  • International Aids Vaccine Initiative, US
  • University of Connecticut, US
  • Ziccum Ab, Sweden
  • Gennova, India
  • Key Contacts

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 2A Pharma Aps
  • Affinivax
  • Bharat Biotech International Limited
  • Codagenix
  • Enovate Biolife
  • Flavex Naturextrakte Gmbh
  • Gennova
  • Gotham Therapeutics Corporation
  • Gpn Vacccines
  • Gradalis Inc.
  • Gyroscope Therapeutics
  • International Aids Vaccine Initiative
  • Minervax
  • Nouscom
  • Providence Therapeutics
  • Rinri Therapeutics
  • Sanaria Inc.
  • Serum Institute of India Pvt. Ltd.
  • University of Connecticut
  • Vaccitech
  • Vaxart
  • Vaxxas Inc.
  • Ziccum Ab